This week, the medical technology companies in the LSI Alumni community made key new appointments, formed collaborations, closed funding rounds, and much more on the road to LSI Europe '24 in Sintra, Portugal this September. Here’s a look at the latest medical device news and achievements from the LSI Alumni.
BrightHeart has announced the appointment of Michael Butchko as the new Chairman of the Board. BrightHeart's AI-powered approach has the potential to revolutionize the screening process for congenital heart defects by offering real-time, expert interpretation of one of the most complex exams in ultrasound practice. This innovation promises to enhance diagnostic accuracy and efficiency, significantly benefiting patients and healthcare providers alike.
Cellens has entered into a collaboration with Bruker BioAFM to develop the world’s first clinical diagnostic tests that utilize multi-parametric, single-cell biophysical markers and machine learning. This partnership aims to provide novel cellular insights on the stage of disease and detect cancer with high accuracy. By combining Cellens' innovative technology with Bruker BioAFM's expertise, the collaboration seeks to transform cancer diagnostics and improve patient outcomes.
Egg Medical has announced the appointment of Jason Gwilliam as Director of OBL & Hospital Business Development. Gwilliam will play a crucial role in expanding the reach of the company’s EggNest™ Radiation Protection System, which aims to reduce radiation exposure for everyone in every case by up to 97% without compromising workflow. This groundbreaking system may enhance safety for both patients and medical staff, making it a vital addition to modern healthcare settings.
ICHOR Vascular has successfully closed its Series A equity round, led by Queen City Angels and syndicated by a group of investors including NuFund Venture Group, Gopher Angels, Florida Community Health Network (FCHN), IrishAngels, Sand Hill Angels, Central Texas Angel Network, and Angel Star Ventures, LLC. The company is aiming to revolutionize peripheral clot removal with its innovative solution for Peripheral Artery Disease (PAD) and Deep Vein Thrombosis (DVT), which may eliminate the need for traditional drug therapies and surgeries.
Ronovo Surgical has raised a $44 million Series B funding round, co-led by venture funds INCE Capital and Guolian Capital. This substantial investment will be used to accelerate the commercialization of Carina, Ronovo’s robotic-assisted surgery (RAS) system. Carina supports laparoscopic surgeries in various medical fields, including urology, gynecology, and general surgery. This funding will help Ronovo Surgical bring its advanced RAS system to a wider market, aiming to enhance surgical precision and patient care.
VenoStent has secured an additional $4 million from Norwest Venture Partners, completing its Series A financing at $20 million with co-lead investments from Good Growth Capital and IAG Capital Partners. Additionally, the company was awarded a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant by the National Institutes of Health. VenoStent’s funding will support the development and commercialization of its innovative products designed to improve vascular surgery outcomes.
Vessl Prosthetics has won Spring’s Women-Led Impact Investor Competition and will receive up to $150,000 in investment funding from a cohort of investors participating in the challenge. Vessl has developed a dynamically adjustable prosthetic socket that aims to eliminate pain around the socket and enable amputees to move comfortably. This innovation represents a significant advancement in prosthetic technology, enhancing mobility and quality of life for amputees.
Veyond Metaverse has announced the launch of Veyond Surgical XR, its cutting-edge 5D XR technology that provides an immersive and interactive learning experience for medical professionals. Committed to dismantling geographical and linguistic barriers, Veyond Metaverse is making advanced surgical care and education universally accessible. This technology has the potential to revolutionize medical training and improve patient care worldwide.
XEOS has welcomed Bodo Wiegand as an independent Advisor. The company is dedicated to improving outcomes in surgical oncology through innovations in molecular intraoperative imaging. With Wiegand’s guidance, XEOS aims to further enhance its technology and expand its impact on cancer treatment.
Stay tuned for more insights and updates on top medical device companies like these LSI Alumni, every Friday on our website and in your inbox.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
